May 19, 2022
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the US market.
May 13, 2022
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
March 19, 2022
Gaps exist in knowledge about interchangeability and substitutions.
February 22, 2022
A new report by Cardinal Health includes research findings on insulin biosimilars use among retail pharmacists and physicians.
February 02, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.
Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.
Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.
December 23, 2021
2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA.
December 01, 2021
By July 2021, the FDA had approved or tentatively approved 470 generic versions of medications.
Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.
